Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Nicotinamide Riboside vs Telmisartan: Nicotinamide Riboside has the stronger overall evidence (5.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Nicotinamide Riboside wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
300–500 mg daily
Morning with breakfast, Split dosing (morning and midday) for doses above 500 mg
Nicotinamide Riboside Chloride capsules or powder
Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.
morning
Oral tablet (telmisartan)
1–2 weeks
4–8 weeks
8–16 weeks
4–8 weeks
Months to years
Weeks to months
Years
Throughout use
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Journal of cachexia, sarcopenia and muscle (2025) · Meta analysis
Systematic review and meta-analysis of RCTs evaluating NMN and NR effects on skeletal muscle mass and function
NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Ageing research reviews (2026) · Systematic review
PRISMA-guided systematic review of both preclinical and clinical NAD+ supplementation literature
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
Experimental gerontology (2020) · Systematic review
Systematic review of 147 articles (113 preclinical, 34 clinical) on NAD+ precursor therapy
Telmisartan, ramipril, or both in patients at high risk for vascular events.
The New England journal of medicine (2008) · Rct · n=25620
ONTARGET randomized 25,620 high-vascular-risk patients to ramipril, telmisartan, or both
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet (London, England) (2008) · Rct · n=25620
Prespecified ONTARGET renal analysis of the same 25,620 patients
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Lancet (London, England) (2008) · Rct · n=5926
TRANSCEND randomized 5,926 ACE-inhibitor-intolerant high-risk patients to telmisartan or placebo
Based on 8-week RCT showing dose-dependent increases of 22%, 51%, and 142% at 100, 300, and 1000mg respectively. Individual response varies significantly (30% show variable response). NR-SAFE trial confirmed safety up to 2000mg.
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide Riboside has a higher evidence score (5.5/10 vs 4.3/10) and wins in 3 of 3 categories.
For support heart health, Telmisartan has a higher relevance score (66 vs 62).
No known interactions between Nicotinamide Riboside and Telmisartan have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.